<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JKMS</journal-id>
      <journal-title-group>
        <journal-title>Journal of Korean Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8934</issn>
      <issn pub-type="epub">1598-6357</issn>
      <publisher>
        <publisher-name>The Korean Academy of Medical Sciences</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21532865</article-id>
      <article-id pub-id-type="pmc">3082126</article-id>
      <article-id pub-id-type="doi">10.3346/jkms.2011.26.5.694</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
          <subj-group>
            <subject>Dermatology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Oral Azithromycin for Treatment of Intractable Rosacea</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Jae-Hong</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oh</surname>
            <given-names>Yoon Seok</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Choi</surname>
            <given-names>Eung Ho</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea.</aff>
      <author-notes>
        <corresp>
Address for Correspondence: Eung Ho Choi, MD. Department of Dermatology, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju 220-701, Korea. Tel: +82.33-741-0623, Fax: +82.33-748-2650, <email>choieh@yonsei.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <volume>26</volume>
      <issue>5</issue>
      <fpage>694</fpage>
      <lpage>696</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>2</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2011 The Korean Academy of Medical Sciences.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Rosacea is a common chronic cutaneous disorder that primarily occurs on the convex surfaces of the central face and is often characterized by exacerbations and remissions. A case of a 52-yr-old woman visited our clinic in February 2008 complaining typical features of rosacea including multiple pinhead to rice-sized erythematous papules. We applied various conventional treatments including topical benzoyl peroxide and metronidazole as well as oral metronidazole, isotretinoin, and doxycycline. The lesions were not controlled but were rather aggravated by complications from these treatments. Therefore, we prescribed oral azithromycin, which has anti-inflammatory effects and reduces reactive oxygen species. Ten weeks after the administration of oral azithromycin, 500 mg per day for 2 weeks, the lesions had mostly disappeared and no specific side effects related to the azithromycin were noted. Oral azithromycin dosing 500 mg/day for 2 weeks is effective for treatment of intractable rosacea.</p>
      </abstract>
      <kwd-group>
        <kwd>Azithromycin</kwd>
        <kwd>Rosacea</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Rosacea is a common skin disease characterized by transient or persistent central facial erythema, visible blood vessels, and frequently, papules and pustules. Treatment of rosacea is usually based on a combination of systemic and topical antibiotics. Since the 1950's, tetracycline and erythromycin are the most commonly used oral antibiotics (<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>). However, long-term treatment with antibiotics is not well tolerated because of side-effects including gastrointestinal intolerance, photosensitivity and candidiasis (<xref ref-type="bibr" rid="B3">3</xref>). Moreover, given the chronic nature of the disease, there is a possibility of developing bacterial resistance (<xref ref-type="bibr" rid="B1">1</xref>). Azithromycin is a newly developed macrolide which offers some advantages compared to previously used antibiotics (<xref ref-type="bibr" rid="B4">4</xref>). It has unique pharmacokinetics that maintains prolonged tissue levels and allows less frequent dosage. Fernandez-Obregon (<xref ref-type="bibr" rid="B5">5</xref>) reported that all of ten patients who were not tolerated or controlled by conventional treatment demonstrated a significant improvement with the oral use of azithromycin. After then, azithromycin has been found to be effective in the intractable rosacea in several clinical reports (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>).</p>
      <p>We report a case of a 52-yr-old rosacea patient who was refractory and complicated by reactions to conventional topical and oral medications. After 10 weeks of oral azithromycin, her lesions had mostly disappeared and the patient suffered no specific side-effects related to the medication. Our case showed that oral azithromycin could be a viable new treatment option for intractable rosacea cases.</p>
    </sec>
    <sec sec-type="cases">
      <title>CASE DESCRIPTION</title>
      <p>A 52-yr-old postmenopausal woman complained of a 10-month history of multiple erythematous papules and some pustules on both cheeks on February 11, 2008 (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The lesions were characterized by progressive extension and continuous flushing. There was neither a familial history of similar lesions nor previous significant medical history. Physical examination revealed multiple pinhead to rice-sized erythematous papules and pustules on both cheeks. Laboratory studies including complete blood cell count (CBC), blood chemistry, and anti-nuclear antibody (ANA) were within normal limits. More than ten demodex mites were observed on the demodex study. On the standard patch test, only nickel sulfate showed a positive response.</p>
      <p>On the basis of medical history and clinical findings, the patient was diagnosed as rosacea. However, her skin lesions were not controlled by topical application of benzoyl peroxide, metronidazole twice a day or crotamiton once a day, or oral administration of doxycycline 200 mg for a month, metronidazole 500 mg for two weeks or isotretinoin 10 mg for a month. Rather her rosacea was aggravated or complicated by these medications. After taking conventional treatment of rosacea, she complained of diffuse facial erythema, swelling and aggravated papules (<xref ref-type="fig" rid="F2">Fig. 2</xref>). We then prescribed oral azithromycin, which has both anti-inflammatory effects and leads to a reduction in reactive oxygen species. Two weeks after oral administration of 500 mg per day of azithromycin, facial erythema and swelling was reduced. Since then, papular lesions which are presented on the cheek were begun to decrease. After 10 weeks of oral azithromycin, the lesions had mostly disappeared, and no specific side-effects related to the medication were noted (<xref ref-type="fig" rid="F3">Fig. 3</xref>). Also until 6 months after treatment, the patient had not experienced any recurrence or aggravation. This patient provided informed written consent prior to usage of her photographs.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Rosacea is a common cutaneous disorder which occurs most frequently in light-skinned middle aged women. There are variable cutaneous signs of rosacea such as flushing, erythema, telangiectasia, edema, papules and pustules (<xref ref-type="bibr" rid="B2">2</xref>).</p>
      <p>While the pathogenesis of rosacea remains unknown, several factors have been implicated including inherent abnormalities in cutaneous vascular homeostasis and dysregulated thermal mechanisms. Recent reports suggest that the effects of reactive oxygen species can contribute to the development of rosacea (<xref ref-type="bibr" rid="B8">8</xref>).</p>
      <p>Conventional treatment of rosacea is based on a combination of systemic and topical antibiotics. Since the 1950's, tetracycline and erythromycin are the most commonly used oral antibiotics (<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>). The therapeutic activity of commonly used antimicrobials including tetracycline, doxycycline has been mainly attributed to their anti-inflammatory activities (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). These results indicate that antibiotics used in the treatment of rosacea affect various inflammatory processes such as the migration of neutrophils, production of pro-inflammatory cytokines including interleukin-1, 6, 8, 10, tumor necrosis factor-&#x3B1;, leukotriene B4, and oxidative burst in phagocytes (<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>). Topical metronidazole and oral tetracyclines effectively treat about 80%-90% of rosacea patients (<xref ref-type="bibr" rid="B6">6</xref>). However, long-term treatment with antibiotics is not well tolerated due to requiring frequent administration, poor compliances and side-effects including gastrointestinal intolerance, photosensitivity and candidiasis (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>). In addition, some patients do not respond to variable combination therapies and rather aggravated by their complications. Modi et al. (<xref ref-type="bibr" rid="B1">1</xref>) reported a rosacea patient who were developed tense bullae and hypopigmented scarring after taking oral doxycycline 100 mg.</p>
      <p>Oral azithromycin is a newly developed macrolide which offers some advantages over previously used antibiotics. It has unique pharmacokinetics that allows it to penetrate into intracellular compartments rapidly and maintain prolonged tissue levels. This allows for less frequent application and shorter duration of treatment which may increase compliance. With its high affinity for inflammatory tissues, azithromycin can achieve steady state tissue levels in approximately 72-96 hr (<xref ref-type="bibr" rid="B14">14</xref>). Moreover, after administration of oral azithromycin, tissue reactive oxygen species, an etiologic factor in the development of rosacea, were greatly decreased in some cases (<xref ref-type="bibr" rid="B7">7</xref>).</p>
      <p>The utility of oral azithromycin was confirmed by several clinical studies. Fernandez-Obregon (<xref ref-type="bibr" rid="B5">5</xref>) reported that all of ten patients who were not tolerated or controlled by conventional treatment of rosacea demonstrated a significant improvement with the oral use of azithromycin. In addition, Modi et al. (<xref ref-type="bibr" rid="B1">1</xref>) treated a 67-yr old man who had photosensitivity to the doxycycline and hyperpigmented dyschromia to the minocycline with an oral use of azithromycin in a dose of 250 mg 3 times weekly. Bakar et al. (<xref ref-type="bibr" rid="B4">4</xref>) reported that treatment with oral azithromycin led to 75% decreases in the total number of lesions and an 89% decrease in inflammatory lesions compared with basal status. Another open-label study showed that azithromycin is as effective as standard dose of doxycycline and has a positive impact on the quality of life of patients compared with conventional treatment regimens (<xref ref-type="bibr" rid="B15">15</xref>).</p>
      <p>Azithromycin may also be an acceptable agent for those using other medications, because it has no known major drug interactions. Additionally, azithromycin shows lower incidences of gastrointestinal discomfort compared with erythromycin (<xref ref-type="bibr" rid="B16">16</xref>). According to one clinical study, only two of 32 patients complained of mild gastric discomfort and no one withdrew from the study due to the side-effects of aztithromycin (<xref ref-type="bibr" rid="B17">17</xref>). In our case, there were no specific side-effects related to the medication.</p>
      <p>In summary, we report a case of a 52-yr-old woman who presented with intractable multiple, pinhead to rice-sized erythematous papules on her face, which were controlled by oral azithromycin. Our case shows that azithromycin could be a new treatment option for the treatment of intractable rosacea.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Modi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Harting</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic</article-title>
          <source>J Drugs Dermatol</source>
          <year>2008</year>
          <volume>7</volume>
          <fpage>898</fpage>
          <lpage>899</lpage>
          <pub-id pub-id-type="pmid">19112809</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>James</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Elston</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <source>Andrew's diseases of the skin</source>
          <year>2006</year>
          <edition>10th ed</edition>
          <publisher-loc>Philadelphia</publisher-loc>
          <publisher-name>WB Sauders</publisher-name>
          <fpage>245</fpage>
          <lpage>349</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Del Rosso</surname>
              <given-names>JQ</given-names>
            </name>
          </person-group>
          <article-title>Systemic therapy for rosacea: focus on oral antibiotic therapy and safety</article-title>
          <source>Cutis</source>
          <year>2000</year>
          <volume>66</volume>
          <issue>4 Suppl</issue>
          <fpage>7</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">11455753</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakar</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Demir&#xE7;ay</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>G&#xFC;rb&#xFC;z</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic potential of azithromycin in rosacea</article-title>
          <source>Int J Dermatol</source>
          <year>2004</year>
          <volume>43</volume>
          <fpage>151</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="pmid">15125511</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Obregon</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Oral use of azithromycin for the treatment of acne rosacea</article-title>
          <source>Arch Dermatol</source>
          <year>2004</year>
          <volume>140</volume>
          <fpage>489</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="pmid">15096385</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Obregon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Patton</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>The role of Chlamydia pneumoniae in the etiology of acne rosacea: response to the use of oral azithromycin</article-title>
          <source>Cutis</source>
          <year>2007</year>
          <volume>79</volume>
          <fpage>163</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="pmid">17388221</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakar</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Demir&#xE7;ay</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yuksel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haklar</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sanisoglu</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>The effect of azithromycin on reactive oxygen species in rosacea</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2007</year>
          <volume>32</volume>
          <fpage>197</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">17244346</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Reactive oxygen species and rosacea</article-title>
          <source>Cutis</source>
          <year>2004</year>
          <volume>74</volume>
          <issue>3 Suppl</issue>
          <fpage>17</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">15499754</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humbert</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Treffel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chapuis</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Buchet</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Derancourt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Agache</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The tetracyclines in dermatology</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1991</year>
          <volume>25</volume>
          <fpage>691</fpage>
          <lpage>697</lpage>
          <pub-id pub-id-type="pmid">1791227</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bannatyne</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Metronidazole, its bioactive metabolites and acne</article-title>
          <source>Curr Med Res Opin</source>
          <year>1999</year>
          <volume>15</volume>
          <fpage>298</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">10640262</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Labro</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Anti-inflammatory activity of macrolides: a new therapeutic potential?</article-title>
          <source>J Antimicrob Chemother</source>
          <year>1998</year>
          <volume>41</volume>
          <issue>Suppl B</issue>
          <fpage>37</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">9579711</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McDonald</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Pruul</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Phagocyte uptake and transport of azithromycin</article-title>
          <source>Eur J Clin Microbiol Infect Dis</source>
          <year>1991</year>
          <volume>10</volume>
          <fpage>828</fpage>
          <lpage>833</lpage>
          <pub-id pub-id-type="pmid">1662626</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scaglione</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rossoni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin</article-title>
          <source>J Antimicrob Chemother</source>
          <year>1998</year>
          <volume>41</volume>
          <issue>Suppl B</issue>
          <fpage>47</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">9579712</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alvarez-Elcoro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Enzler</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>The macrolides: erythromycin, clarithromycin, and azithromycin</article-title>
          <source>Mayo Clin Proc</source>
          <year>1999</year>
          <volume>74</volume>
          <fpage>613</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="pmid">10377939</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akhyani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ehsani</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Ghiasi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jafari</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial</article-title>
          <source>Int J Dermatol</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>284</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="pmid">18289334</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torresani</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Clarithromycin: a new perspective in rosacea treatment</article-title>
          <source>Int J Dermatol</source>
          <year>1998</year>
          <volume>37</volume>
          <fpage>347</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="pmid">9620480</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dereli</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inanir</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kilin&#xE7;</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gen&#xE7;o&#x11F;lan</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Azithromycin in the treatment of papulopustular rosacea</article-title>
          <source>J Dermatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>926</fpage>
          <lpage>928</lpage>
          <pub-id pub-id-type="pmid">16361757</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Multiple pinhead to rice-sized erythematous papules, typical features of rosacea, were present on both cheeks.</p>
      </caption>
      <graphic xlink:href="jkms-26-694-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>The patient's skin lesions were not controlled by conventional treatments for rosacea, but rather, were aggravated.</p>
      </caption>
      <graphic xlink:href="jkms-26-694-g002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Fig. 3</label>
      <caption>
        <p>Ten weeks after taking oral azithromycin, the patient's skin lesions had mostly disappeared.</p>
      </caption>
      <graphic xlink:href="jkms-26-694-g003"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
